Genistein enhances the effect of cisplatin on the inhibition of non‑small cell lung cancer A549 cell growth in vitro and in vivo

Liu,Dezhi; Yan,Ling; Wang,Lan; Tai,Weicheng; Wang,Weili; Yang,Changbin

doi:10.3892/ol.2014.2597

Genistein enhances the effect of cisplatin on the inhibition of non‑small cell lung cancer A549 cell growth in vitro and in vivo

Authors:
- Dezhi Liu
- Ling Yan
- Lan Wang
- Weicheng Tai
- Weili Wang
- Changbin Yang
View Affiliations

Affiliations: Department of Radiation Oncology, The Tumor Hospital of Jilin Province, Changchun, Jilin 130012, P.R. China
Published online on: October 9, 2014 https://doi.org/10.3892/ol.2014.2597
Pages: 2806-2810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although cisplatin (DDP) has been reported to be a promising antitumor therapy for non‑small cell lung cancer (NSCLC), the effectiveness of the treatment remains limited due to an inherent tumor resistance to DDP. Genistein (GEN) is an abundant, naturally occurring isoflavonoid found in soy products that has been demonstrated to increase the anti‑neoplastic activity of certain chemotherapy drugs in multiple tumor types. In the present study, DDP in combination with GEN was selected as a potential treatment to suppress tumor growth and simultaneously reduce the doses of the two drugs required for the treatment of NSCLC. Cell growth inhibition, apoptosis, cell cycle distribution and receptor signaling assays were conducted. In the in vivo study, DDP and GEN, either alone or in combination, were used to treat a xenograft model of the A549 cells. It was found that the combination of low concentrations of DDP and GEN induced significantly greater growth inhibition (P<0.01) and increased apoptosis in the A549 cells compared with either agent alone. In addition, DDP in combination with GEN could significantly suppress tumor growth in vivo compared with either agent alone. Combination treatment significantly suppresses constitutive phosphorylation of AKT and phosphoinositide‑3 kinase, which may contribute to the inhibition of tumor growth. Overall, the present data suggested that GEN can increase the anti‑neoplastic activity of DDP and that a combination of GEN and DDP is a potential drug candidate for the treatment of NSCLC.

View Figures

View References

1	Méndez M, Custodio A and Provencio M: New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis. 3:30–56. 2011.
2	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009.
3	Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int. 2013:9647432013.
4	Raez LE and Lilenbaum R: Chemotherapy for advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2:173–178. 2004.
5	Rinaldi M, Belvedere O, Cauchi C, et al: Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol. 17(Suppl 2): ii67–ii70. 2006.
6	Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011.
7	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006.
8	Gadgeel SM, Ali S, Philip PA, Wozniak A and Sarkar FH: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer. 115:2165–2176. 2009.
9	Li Q and Chen H: Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis. Epigenetics. 6:849–852. 2011.
10	Nagata Y, Sonoda T, Mori M, et al: Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 137:1974–1979. 2007.
11	Ali S, Varghese L, Pereira L, et al: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett. 278:201–209. 2009.
12	Lattrich C, Lubig J, Springwald A, et al: Additive effects of trastuzumab and genistein on human breast cancer cells. Anticancer Drugs. 22:253–261. 2011.
13	Schabath MB, Hernandez LM, Wu X, Pillow PC and Spitz MR: Dietary phytoestrogens and lung cancer risk. JAMA. 294:1493–1504. 2005.
14	Mai Z, Blackburn GL and Zhou JR: Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog. 46:534–542. 2007.
15	Mohammad RM, Banerjee S, Li Y, et al: Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer. 106:1260–1268. 2006.
16	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.
17	Petty RD, Nicolson MC, Skaria S, et al: Aberdeen Pancreatic Cancer Focus Group: A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol. 14:1100–1105. 2003.
18	Rajeswaran A, Trojan A, Burnand B and Giannelli M: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer. 59:1–11. 2008.
19	Choi YH, Zhang L, Lee WH and Park KY: Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol. 13:391–396. 1998.
20	Choi YH, Lee WH, Park KY and Zhang L: p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res. 91:164–173. 2000.
21	Sarkar FH, Adsule S, Padhye S, Kulkarni S and Li Y: The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem. 6:401–407. 2006.
22	Thasni KA, Rojini G, Rakesh SN, et al: Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur J Pharmacol. 588:158–164. 2008.
23	Li Y, Ahmed F, Ali S, et al: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65:6934–6942. 2005.
24	Jeong SY and Seol DW: The role of mitochondria in apoptosis. BMB Rep. 41:11–22. 2008.
25	Cohen GM: Caspases: the executioners of apoptosis. Biochem J. 326(Pt 1): 1–16. 1997.
26	Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 68:383–424. 1999.
27	Gagnon V, Van Themsche C, Turner S, Leblanc V and Asselin E: AKT and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 13:259–271. 2008.
28	McDonald GT, Sullivan R, Paré GC and Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res. 316:3197–3206. 2010.
29	Chekenya M, Krakstad C, Svendsen A, et al: The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/AKT signaling. Oncogene. 27:5182–5194. 2008.
30	Li Y and Sarkar FH: Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via AKT signaling pathway. Clin Cancer Res. 8:2369–2377. 2002.
31	Park SY and Seol DW: Regulation of AKT by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun. 295:515–518. 2002.